Niagen Bioscience, Inc.NASDAQ: NAGE

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

· Issued by Niagen Bioscience, Inc. via Business Wire

Summary by 6ix AI

Niagen Bioscience, Inc., which makes products based on NAD+ (nicotinamide adenine dinucleotide, a coenzyme found in every cell), said senior leadership will participate in four investor conferences between November 11 and December 12, 2026.

Key details

  • A.G.P. Virtual Consumer Showcase, held virtually November 11 - 12, 2026: fireside chat with CEO Rob Fried and CFO Ozan Pamir on Thursday, November 12, 2026 at 3:00 p.m. ET.
  • Southwest IDEAS Investor Conference, The Westin Irving Convention Center in Las Colinas, Irving, Texas, November 18 - 19, 2026: presentation on Thursday, November 19, 2026 from 4:00 - 4:35 p.m. CT plus one-on-one meetings, with Rob Fried and Ozan Pamir.
  • 15th Annual ROTH Deer Valley Event, an invite-only conference at Montage Deer Valley, Park City, Utah, December 9 - 12, 2026: one-on-one meetings with CEO Rob Fried.
  • StoneX 15th Annual Discovery Conference 2026, New York Athletic Club, New York, December 10, 2026: one-on-one meetings with CFO Ozan Pamir.
  • Investors can request one-on-one meetings through their conference representative or by emailing Niagen@KCSA.com.

6ix AI wrote this summary from the release below and checked it against the release.

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences:

A.G.P. Virtual Consumer Showcase

  • Virtual showcase offering consumer company management teams a platform to share their story with the investment community
  • Location: Virtual
  • Date: November 11 - 12, 2026
  • Format: Fireside chat Thursday, November 12, 2026 at 3:00 p.m. ET
  • Management: Rob Fried, CEO & Ozan Pamir, CFO
  • Investors may register here

Southwest IDEAS Investor Conference

  • Independent institutional investor conference for publicly traded companies and institutional investors
  • Location: The Westin Irving Convention Center in Las Colinas, Irving, Texas
  • Date: November 18 - 19, 2026
  • Format: Presentation on Thursday, November 19, 2026 from 4:00 - 4:35 p.m. CT and one-on-one meetings
  • Management: Rob Fried, CEO & Ozan Pamir, CFO

15th Annual ROTH Deer Valley Event

  • Invite-only annual networking conference for institutional investors and select public/private company management teams.
  • Location: Montage Deer Valley Park City, Utah
  • Date: December 9 - 12, 2026
  • Format: One-on-one meetings
  • Management: Rob Fried, CEO

StoneX 15th Annual Discovery Conference 2026

  • Emerging growth investor forum for institutional investors and select public and private emerging growth companies.
  • Location: New York Athletic Club New York, New York
  • Date: December 10, 2026
  • Format: One-on-one meetings
  • Management: Ozan Pamir, CFO

If you would like to schedule a one-on-one meeting with the Niagen management team during either conference, please contact your respective conference representative or email Niagen@KCSA.com.

For additional information on Niagen Bioscience, visit www.niagenbioscience.com.

About Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.

At the heart of its clinically tested product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company’s wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated small molecule.

Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.

†Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025)

View original source (Business Wire)Niagen Bioscience, Inc. on 6ix

Earlier from Niagen Bioscience

Later from Niagen Bioscience

All Niagen Bioscience news releases